BridgeMD
New treatment option for Stage III Non-small-cell Lung Cancer
Official title Heterogeneously Hypofractionated Radiotherapy for Locally Advanced NSCLC
ClinicalTrials.gov ID: NCT03742687
What this study is testing
- What it's testing
- The options for patients with locally advanced non-small cell lung cancer (NSCLC) who are not candidates for a standard definitive chemoradiotherapy regime are meagre. These are patients who are not fit for a chemoradiotherapy schedule of 66 Gy in 2 Gy fractions due to either tumour extent, resulting in excessive dose to the healthy tissue in the thorax, or with performance status not supporting seven weeks of intensive treatment.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Histologically or cytological confirmed locally advanced, inoperable NSCLC.
- Age ≥18 years.
- Signed informed consent.
- Performance status 0-2.
- Able to comply with study and follow-up procedures.
You likely can't join if
- Prior radiotherapy to the thorax, unless there is no significant overlap of current treatment volumes with previous treatment fields.
- Dose plan conforming to protocol planning criteria not possible.
- Uncontrolled metastatic disease.
- Other active malignant disease.
See the full eligibility criteria
- Histologically or cytological confirmed locally advanced, inoperable NSCLC.
- Age ≥18 years.
- Signed informed consent.
- Performance status 0-2.
- Able to comply with study and follow-up procedures.
- Fertile women must have a negative pregnancy test. Fertile men and women must use effective contraception. Fertile women included in the study must use the pill, spiral, depot injection of gestagen, subdermal...
- Prior radiotherapy to the thorax, unless there is no significant overlap of current treatment volumes with previous treatment fields.
- Dose plan conforming to protocol planning criteria not possible.
- Uncontrolled metastatic disease.
- Other active malignant disease.
The study team makes the final eligibility decision.
Where it's taking place
- Aarhus, Denmark
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Aarhus, Denmark. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.